Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin -: Clinical pathophysiology and natural history of β-cell dysfunction and insulin resistance

被引:189
作者
Mauvais-Jarvis, F
Sobngwi, E
Porcher, R
Riveline, JP
Kevorkian, JP
Vaisse, C
Charpentier, G
Guillausseau, PJ
Vexiau, P
Gautier, JF
机构
[1] Saint Louis Hosp, Dept Endocrinol & Diabet, Paris, France
[2] Univ Paris 07, Sch Med, Paris, France
[3] Saint Louis Hosp, Dept Med Biostat, Paris, France
[4] Sud Francilien Hosp, Dept Diabet & Metab Dis, Corbeil Essonnes, France
[5] Lariboisiere Hosp, Dept Internal Med B, Paris, France
[6] Univ Calif San Francisco, Dept Med, Diabet Res Ctr, San Francisco, CA USA
关键词
D O I
10.2337/diabetes.53.3.645
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonautoimmune ketosis-prone diabetic syndromes are increasingly frequent in nonwhite populations. We have characterized a cohort of patients of sub-Saharan African origin who had ketosis-prone type 2 diabetes (n = 111), type I diabetes (n = 21), and type 2 diabetes (n = 88) and were admitted to a hospital for management of uncontrolled diabetes. We compared epidemiological, clinical, and metabolic features at diabetes onset and measured insulin secretion (glucagon-stimulated C-peptide) and insulin action (short intravenous insulin tolerance test) during a 10-year follow-up. Ketosis-prone type 2 diabetes shows a strong male predominance, stronger family history, higher age and BMI, and more severe metabolic decompensation than type 1 diabetes. In ketosis-prone type 2 diabetes, discontinuation of insulin therapy with development of remission of insulin dependence is achieved in 76% of patients (noninsulin dependent), whereas only 24% of patients remain insulin dependent. During evolution, ketosisprone type 2 diabetes exhibit specific beta-cell dysfunction features that distinguish it from type 1 and type 2 diabetes. The clinical course of non-insulin-dependent ketosis-prone type 2 diabetes is characterized by ketotic relapses followed or not by a new remission. Progressive hyperglycemia precedes and is a strong risk factor for ketotic relapses (hazard ratio 38). The probability for non-insulin-dependent ketosis-prone type 2 diabetes to relapse is 90% within 10 years, of whom similar to50% will become definitively insulin dependent. Insulin sensitivity is decreased in equal proportion in both ketosis-prone type 2 diabetes and type 2 diabetes, but improves significantly in non-insulin-dependent ketosis-prone type 2 diabetes, only after correction of hyperglycemia. In conclusion, ketosis-prone type 2 diabetes can be distinguished from type I diabetes and classical type 2 diabetes by specific features of clinical pathophysiology and also by the natural history of P-cell dysfunction and insulin resistance reflecting a propensity to glucose toxicity.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 39 条
  • [1] Ahren B, 1985, Diabet Med, V2, P262
  • [2] Aizawa T, 1997, DIABETIC MED, V14, P989
  • [3] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [4] 2-S
  • [5] Insulin secretion, insulin sensitivity and diabetes in black children
    Arslanian, S
    Danadian, K
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (05) : 194 - 199
  • [6] New profiles of diabetic ketoacidosis -: Type 1 vs type 2 diabetes and the effect of ethnicity
    Balasubramanyam, A
    Zern, JW
    Hyman, DJ
    Pavlik, V
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (19) : 2317 - 2322
  • [7] GAD ANTIBODY NEGATIVE NIDDM IN ADULT BLACK SUBJECTS WITH DIABETIC-KETOACIDOSIS AND INCREASED FREQUENCY OF HUMAN-LEUKOCYTE ANTIGEN DR3 AND DR4 - FLATBUSH DIABETES
    BANERJI, MA
    CHAIKEN, RL
    HUEY, H
    TUOMI, T
    NORIN, AJ
    MACKAY, IR
    ROWLEY, MJ
    ZIMMET, PZ
    LEBOVITZ, HE
    [J]. DIABETES, 1994, 43 (06) : 741 - 745
  • [8] IMMUNOLOGY AND DIABETES WORKSHOP - REPORT ON THE 3RD INTERNATIONAL (STAGE-3) WORKSHOP ON THE STANDARDIZATION OF CYTOPLASMIC ISLET CELL ANTIBODIES HELD IN NEW-YORK, NEW-YORK, OCTOBER 1987
    BOITARD, C
    BONIFACIO, E
    BOTTAZZO, GF
    GLEICHMANN, H
    MOLENAAR, J
    [J]. DIABETOLOGIA, 1988, 31 (07) : 451 - 452
  • [9] Boutin P, 1999, DIABETOLOGIA, V42, P380
  • [10] EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360